Inhibrx INBRX-109 Phase 1 Ewing Sarcoma Clinical Trial 2021

Inhibrx presents preclinical and clinical data for INBRX-109, a tetravalent DR5 agonist antibody in development for Ewing sarcoma. The Phase 1 trial (NCT03715933) demonstrates tolerability through dose escalation with robust in vitro and in vivo anti-tumor activity in Ewing sarcoma models. An expansion cohort combining INBRX-109 with irinotecan and temozolomide opened in September 2021 for patients with metastatic or unresectable disease.